<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789033</url>
  </required_header>
  <id_info>
    <org_study_id>030-2010</org_study_id>
    <nct_id>NCT02789033</nct_id>
  </id_info>
  <brief_title>Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers</brief_title>
  <official_title>Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of diabetic foot ulceration in the diabetic population is 4-10%; the condition&#xD;
      is more frequent in elder patients. It is estimated that about 5% of all patients with&#xD;
      diabetes present a history of foot ulceration, while the lifetime risk of diabetic patients&#xD;
      developing this complication is 15%. The majority (60-80%) of foot ulcers will heal, while&#xD;
      10-15% of them will remain active, and 5-24% of them will finally lead to limb amputation&#xD;
      within a period of 6-18 months after the first evaluation , 2 out of 3 patients with a limb&#xD;
      amputation could also be involved in a new amputation in the next year; higher or in the&#xD;
      other leg , Eighty-five percent of lower-limb amputations in patients with diabetes are&#xD;
      preceded by foot ulceration. The management of chronic diabetic foot ulcers (DFU) suggests&#xD;
      multi-disciplinary approaches including control of diabetes, orthotic shoe wear, off-loading&#xD;
      device, wound care and surgery in selected cases. However, treatment of DFU remains&#xD;
      challenging because of unsatisfactory results from surgical and non-surgical treatments. Many&#xD;
      adjunctive therapies are designed to improve the care of DFU including negative pressure&#xD;
      wound therapy , ultrasound, recombinant human platelet-derived growth factor-BB (rPDGF-BB)&#xD;
      Hyperbaric oxygen and acellular matrix product among others.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, placebo controlled, double-blind Clinical trial was designed. 60 Patients with&#xD;
      diabetic foot ulcers in grade I and II of the classification of Wagner, with leg arm index&gt;&#xD;
      0.8 and without specific treatment for foot ulcers referred to the experimental and clinical&#xD;
      Therapeutic Institute will be included. All patients give written informed consent;&#xD;
      previously the protocol was approved for the bioethics committee of the CUCS, of the&#xD;
      Guadalajara University, registration number 030-2010. Patients with another type of topical&#xD;
      medication will be excluded. Isosorbide dinitrate spray (2.5 mg).&#xD;
&#xD;
      Preparation of chitosan Hydrogels: The composition of gel formulation will be given prior&#xD;
      training. ISDN and chitosan gel will be applied handled under aseptic conditions to the&#xD;
      wound, and covered with sterile bandages. The patients will be evaluated every 2 weeks&#xD;
      (macroscopic study and measurement of the ulcerated area) until 6 views. A second biopsy will&#xD;
      be done one week before the finalization of the treatment of 15 weeks. The biopsies will be&#xD;
      embedded on paraformaldehyde (4%) and paraffin. Sections of 5 µm were analyzed by a&#xD;
      pathologist to determine hypertrophic and hyperplasic capillaries, inflammation and cellular&#xD;
      matrix using Hematoxylin &amp; eosin and Masson's trichrome stains. An immunohistochemical stain&#xD;
      was also realized to evaluate several molecular markers such as α-SMA (abcam, Cambridge, MA),&#xD;
      Desmin (abcam, Cambridge, MA), VEGF (abcam, Cambridge, MA) and Von Willebrand Factor&#xD;
      (Chemicon, CA). (figure 1) Statistical analysis: It will be done using SPSS program for&#xD;
      Windows Version 10.0, the results of quantitative variables were expressed in average and&#xD;
      standard deviation. The differences between baseline and subsequent pharmacologic&#xD;
      intervention measurements will be investigated with the Wilcoxon test. The Mann Whitney U&#xD;
      test will be used to compare groups. Frequencies by categories as well as percentages will be&#xD;
      quantified for qualitative variables. Comparisons between groups were performed with Chi2.&#xD;
      For all comparisons p &lt; 0.05 will be considered as significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsies</measure>
    <time_frame>75 days</time_frame>
    <description>Histological changes in ulcers</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Chitosan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isosorbide dinitrate spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in the same pharmacological presentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chitosan</intervention_name>
    <description>Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine</description>
    <arm_group_label>Chitosan</arm_group_label>
    <arm_group_label>Isosorbide dinitrate spray</arm_group_label>
    <other_name>polymers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide dinitrate</intervention_name>
    <description>Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate</description>
    <arm_group_label>Chitosan</arm_group_label>
    <arm_group_label>Isosorbide dinitrate spray</arm_group_label>
    <other_name>organic nitrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Magnessium Calcuim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diabetic foot ulcers in grade I and II of the classification of Wagner&#xD;
&#xD;
          -  with leg arm index&gt; 0.8 and&#xD;
&#xD;
          -  without specific treatment for foot ulcers referred to the experimental and clinical&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with another type of topical medication&#xD;
&#xD;
          -  patients with diabetic foot ulcers in grade III and&#xD;
&#xD;
          -  with leg arm index &lt;0.8&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonel Garcia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <link>
    <url>http://www.hindawi.com/journals/ecam/2013/243568/</url>
    <description>The outcome of management of diabetic foot ulceration (DFU) is poor and insufficient. DFU therapy includes the standard management as debridement of the wound, revascularization procedures,off-loading of the ulcer and antibacterial actions,</description>
  </link>
  <reference>
    <citation>Alexiadou K, Doupis J. Management of diabetic foot ulcers. Diabetes Ther. 2012 Nov;3(1):4. doi: 10.1007/s13300-012-0004-9. Epub 2012 Apr 20.</citation>
    <PMID>22529027</PMID>
  </reference>
  <reference>
    <citation>Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg. 1998 Aug;176(2A Suppl):5S-10S. Review.</citation>
    <PMID>9777967</PMID>
  </reference>
  <reference>
    <citation>Xie X, McGregor M, Dendukuri N. The clinical effectiveness of negative pressure wound therapy: a systematic review. J Wound Care. 2010 Nov;19(11):490-5. Review. Erratum in: J Wound Care. 2011 Feb;20(2):89.</citation>
    <PMID>21135797</PMID>
  </reference>
  <reference>
    <citation>Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The role of hyperbaric oxygen in the treatment of diabetic foot ulcers. Angiology. 2012 May;63(4):302-14. doi: 10.1177/0003319711416804. Epub 2011 Aug 25. Review.</citation>
    <PMID>21873346</PMID>
  </reference>
  <reference>
    <citation>Schäffer MR, Tantry U, Efron PA, Ahrendt GM, Thornton FJ, Barbul A. Diabetes-impaired healing and reduced wound nitric oxide synthesis: a possible pathophysiologic correlation. Surgery. 1997 May;121(5):513-9.</citation>
    <PMID>9142149</PMID>
  </reference>
  <reference>
    <citation>Andrews KL, Irvine JC, Tare M, Apostolopoulos J, Favaloro JL, Triggle CR, Kemp-Harper BK. A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. Br J Pharmacol. 2009 Jun;157(4):540-50. doi: 10.1111/j.1476-5381.2009.00150.x. Epub 2009 Mar 26.</citation>
    <PMID>19338582</PMID>
  </reference>
  <reference>
    <citation>Raafat D, von Bargen K, Haas A, Sahl HG. Insights into the mode of action of chitosan as an antibacterial compound. Appl Environ Microbiol. 2008 Jun;74(12):3764-73. doi: 10.1128/AEM.00453-08. Epub 2008 May 2. Erratum in: Appl Environ Microbiol. 2008 Dec;74(23):7455.</citation>
    <PMID>18456858</PMID>
  </reference>
  <reference>
    <citation>Sezer AD, Cevher E, Hatipoğlu F, Oğurtan Z, Baş AL, Akbuğa J. Preparation of fucoidan-chitosan hydrogel and its application as burn healing accelerator on rabbits. Biol Pharm Bull. 2008 Dec;31(12):2326-33.</citation>
    <PMID>19043221</PMID>
  </reference>
  <reference>
    <citation>Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract. 2006 Nov;60(11):1471-83. Review.</citation>
    <PMID>17073842</PMID>
  </reference>
  <reference>
    <citation>Chabbert-Buffet N, LeDevehat C, Khodabandhelou T, Allaire E, Gaitz JP, Tribout L, Abdoucheli-Baudot N, Vayssairat M. Evidence for associated cutaneous microangiopathy in diabetic patients with neuropathic foot ulceration. Diabetes Care. 2003 Mar;26(3):960-1.</citation>
    <PMID>12610079</PMID>
  </reference>
  <reference>
    <citation>Richards AM, Floyd DC, Terenghi G, McGrouther DA. Cellular changes in denervated tissue during wound healing in a rat model. Br J Dermatol. 1999 Jun;140(6):1093-9.</citation>
    <PMID>10354076</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <results_first_submitted>November 23, 2020</results_first_submitted>
  <results_first_submitted_qc>December 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2021</results_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Leonel Garcia Benavides</investigator_full_name>
    <investigator_title>Professor researcher</investigator_title>
  </responsible_party>
  <keyword>diabetic foot ulcers</keyword>
  <keyword>chitosan</keyword>
  <keyword>isosorbide dinitrate spray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Chitosan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>ADDITIONAL PARTICIPANTS WERE INCLUDED ANTICIPATING PARTICIPANTS WHO DO NOT COMPLETE THE CLINICAL TRIAL</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Comparator: Chitosan</title>
          <description>Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine&#xD;
And&#xD;
Placebo in the same pharmacological presentation that Isosorbide dinitrate spray</description>
        </group>
        <group group_id="P2">
          <title>Active Comparator: Isosorbide Dinitrate Spray</title>
          <description>Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.&#xD;
And&#xD;
Placebo in the same pharmacological presentation that Chitosan</description>
        </group>
        <group group_id="P3">
          <title>Combination: IDS and Chitosan</title>
          <description>Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.&#xD;
And&#xD;
Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine</description>
        </group>
        <group group_id="P4">
          <title>Placebo Comparator: Placebo</title>
          <description>Placebo in the same pharmacological presentation that both, IDS and Chitosan.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Comparator: Chitosan</title>
          <description>Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine&#xD;
And&#xD;
Placebo in the same pharmacological presentation that Isosorbide dinitrate spray</description>
        </group>
        <group group_id="B2">
          <title>Active Comparator: Isosorbide Dinitrate Spray</title>
          <description>Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.&#xD;
And&#xD;
Placebo in the same pharmacological presentation that Chitosan</description>
        </group>
        <group group_id="B3">
          <title>Combination: IDS and Chitosan</title>
          <description>Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.&#xD;
And&#xD;
Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine</description>
        </group>
        <group group_id="B4">
          <title>Placebo Comparator: Placebo</title>
          <description>Placebo in the same pharmacological presentation that both, IDS and Chitosan.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diameter of the ulcer</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="5.8"/>
                    <measurement group_id="B2" value="12.1" spread="7.0"/>
                    <measurement group_id="B3" value="11.4" spread="8.2"/>
                    <measurement group_id="B4" value="15.8" spread="9.3"/>
                    <measurement group_id="B5" value="12.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biopsies</title>
        <description>Histological changes in ulcers</description>
        <time_frame>75 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator: Chitosan</title>
            <description>Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine&#xD;
And&#xD;
Placebo in the same pharmacological presentation that Isosorbide dinitrate spray</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator: Isosorbide Dinitrate Spray</title>
            <description>Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.&#xD;
And&#xD;
Placebo in the same pharmacological presentation that Chitosan</description>
          </group>
          <group group_id="O3">
            <title>Combination: IDS and Chitosan</title>
            <description>Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.&#xD;
And&#xD;
Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator: Placebo</title>
            <description>Placebo in the same pharmacological presentation that both, IDS and Chitosan.</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsies</title>
          <description>Histological changes in ulcers</description>
          <units>UI/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>α-smooth muscle actin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="0.6"/>
                    <measurement group_id="O2" value="2.64" spread="0.6"/>
                    <measurement group_id="O3" value="2.56" spread="0.6"/>
                    <measurement group_id="O4" value="2.07" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Von Willebrand Factor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.65"/>
                    <measurement group_id="O2" value="2.28" spread="0.82"/>
                    <measurement group_id="O3" value="2.31" spread="0.8"/>
                    <measurement group_id="O4" value="2.15" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vascular endothelial growth factor-A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="0.8"/>
                    <measurement group_id="O2" value="2.6" spread="0.6"/>
                    <measurement group_id="O3" value="2.43" spread="0.6"/>
                    <measurement group_id="O4" value="2.07" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>desmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.8"/>
                    <measurement group_id="O2" value="2.5" spread="0.6"/>
                    <measurement group_id="O3" value="2.6" spread="0.6"/>
                    <measurement group_id="O4" value="2.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Chitosan and isosorbide dinitrate are widely used substances, in addition they were used in regular doses for a short period of time, locally.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Comparator: Chitosan</title>
          <description>Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine&#xD;
And&#xD;
Placebo in the same pharmacological presentation that Isosorbide dinitrate spray</description>
        </group>
        <group group_id="E2">
          <title>Active Comparator: Isosorbide Dinitrate Spray</title>
          <description>Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.&#xD;
And&#xD;
Placebo in the same pharmacological presentation that Chitosan</description>
        </group>
        <group group_id="E3">
          <title>Combination: IDS and Chitosan</title>
          <description>Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.&#xD;
And&#xD;
Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine</description>
        </group>
        <group group_id="E4">
          <title>Placebo Comparator: Placebo</title>
          <description>Placebo in the same pharmacological presentation that both, IDS and Chitosan.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>PhD. Leonel García Benavides</name_or_title>
      <organization>Universidad de Guadalajara</organization>
      <phone>+52 (33) 20 00 23 00 ext 64096</phone>
      <email>drleonelgb@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

